Cell cycle control factors and skeletal development  by Ogasawara, Toru
Review Article
Cell cycle control factors and skeletal development
Toru Ogasawara *
Department of Oral and Maxillofacial Surgery, Graduate School and Faculty of Medicine, The University of Tokyo, Tokyo 113-8655,
Japan
Received 5 September 2012; received in revised form 5 February 2013; accepted 9 March 2013
Available online 15 April 2013
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
2. Cdks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
2.1. Cdk2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
2.2. Cdk4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
2.3. Cdk6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
3. Cyclins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.1. Cyclin A (A1 and A2). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.2. Cyclin B (B1 and B2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.3. Cyclin D (D1, D2 and D3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.4. Cyclin E (E1 and E2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Japanese Dental Science Review (2013) 49, 79—87
KEYWORDS
Cell cycle;
Transcription factor;
Cdk;
Cyclin;
CKI
Summary In the oral and maxillofacial region, conditions such as delayed bone healing after
tooth extraction, bone fracture, trauma-induced bone or cartilage defects, and tumors or birth
defects are common, and it is necessary to identify the molecular mechanisms that control
skeletogenesis or the differentiation of cells, in order to establish new treatment strategies for
these conditions. Multiple studies have been conducted to investigate the involvement of factors
that may be crucial for skeletogenesis or the differentiation of cells, including transcription
factors, growth factors and cell cycle factors. Several genetically engineered mouse models of cell
cycle factors have been generated in research seeking to identify cell cycle factor(s) involved in
the differentiation of cells, carcinogenesis, etc. Many groups have also reported the importance of
cell cycle factors in the differentiation of osteoblasts, osteoclasts, chondrocytes and other cell
types. Herein, we review the phenotypes of the genetically engineered mouse models of cell cycle
factors with a particular focus on the size, body weight and skeletal abnormalities of the mice, and
we discuss the potential of cell cycle factors as targets of clinical applications.
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In the oral and maxillofacial region, conditions such as
delayed bone healing after tooth extraction, bone fractures,
tumors or birth defects and trauma-induced bone or cartilage
defects are common, and it is necessary to elucidate the
molecular mechanisms which control skeletogenesis and the
differentiation of stem cells, osteoblasts, osteoclasts and
chondrocytes to establish new treatment strategies for these
conditions. Bone grafts are the current gold-standard strat-
egy to repair irreversible skeletal damage or defects, but the
use of bone grafts often entails problems with respect to the
availability of bone graft material, difficulties with the donor
site, and other factors. Thus, in order to establish new
treatment strategies for such conditions, an important goal
is to shed light on the molecular mechanisms that control
skeletogenesis and the differentiation of cells.
Numerous studies have been performed in vitro and in
vivo to investigate the involvement of factors that are
thought to be crucial for skeletogenesis or the differentiation
of cells; such factors include transcription factors, growth
factors and cell cycle factors. In particular, cell cycle factors
are thought to significantly influence the differentiation of
cells, since withdrawal from the cell cycle or a temporal
arrest in the G1 phase of the cell cycle is thought to be a
requirement for cell differentiation [1—3]. The proliferation
of eukaryotic cells depends on their progression through the
cell cycle. The cell cycle is controlled by many cell cycle
control factors, namely cyclins, cyclin-dependent kinases
(Cdks) and cyclin-dependent kinase inhibitors (CKIs). Cyclins
and Cdks, which are positive regulators of the cell cycle,
activate cell cycle factors that are essential for the start of
the next cell cycle phase. In contrast, CKIs function as
negative regulator of Cdks by direct binding to cyclins and
Cdks [2,4]. In mammalian cells, the activities of the Cyclin D-
dependent kinases Cdk4 and/or Cdk6 and those of the Cyclin
E-dependent kinase Cdk2 are required to pass through the G1
phase and the subsequent S-phase entry [5].Retinoblastoma (Rb) protein is a member of a protein family
that also includes p107 and p130. It is a key physiological
substrate for Cdk4 and Cdk6, which binds and inactivates the
E2F-DP transcription complexes essential for S-phase entry
[6,7]. The phosphorylation of pRb by Cdk4/6 and additionally
by Cdk2 reverses the growth-suppressive effects of pRb by
releasing E2F-DP from inactivation and consequently promot-
ing S-phase entry and progression. Cdk4 and Cdk6 have 71%
amino acid identity and are structurally homologous. They
share all three D-type cyclins, i.e., CyclinD1, CyclinD2, and
CyclinD3, as their catalytic partners to phosphorylate pRb in
vitro [6]. As a result, Cdk4 and Cdk6 had been proposed to
function redundantly in the G1 phase of the cell cycle.
In contrast to the D-type cyclins, Cyclin E is expressed
periodically, binding to Cdk2 and inducing Cyclin E-depen-
dent kinase activity to maximal levels at the G1—S transition
[8,9]. Once cells enter the S phase, Cyclin E is degraded, and
subsequently Cdk2 forms complexes with Cyclin A. CKIs have
been classified into two families: the INK4 family and the Cip/
Kip family. Generally, the INK4 family (p16, p15, p18, and
p19) inhibits only Cdk4 and Cdk6, whereas the Cip/Kip family
(p21, p27, and p57) inhibits all the Cdks in vitro [2].
A schematic presentation of cell cycle regulation in the G1
phase is shown in Fig. 1. Because a temporal cell cycle arrest
in the G1 phase or withdrawal from the cell cycle is regarded
as a prerequisite for cell differentiation, herein we review
the phenotypes of genetically engineered mouse models of
the representative G1 cell cycle factors with a particular
focus on the size, body weight and skeletal abnormality, and
we discuss the potential of cell cycle factors as targets of
clinical applications.
2. Cdks
2.1. Cdk2
At birth, homozygous Cdk2-deficient mice did not differ
in any obvious way from their control littermates. They
Figure 1 Cell cycle factors that function in the G1 phase. Cell cycle progression is controlled by the action of cyclins and cyclin-
dependent kinases (Cdks), which phosphorylate and activate cell cycle factors that are crucial for the start of the next cell cycle phase.
In contrast, cell cycle arrest is thought to be controlled chiefly by Cdk inhibitors (CKIs), which inhibit Cdks or Cdk-cyclin complexes. In
general, the INK4 family (p16, p15, p18, and p19) inhibits only Cdk4 and Cdk6 by interfering with their binding to cyclins (A), whereas
the Cip/Kip family (p21, p27, and p57) binds to Cdk-cyclin complexes and inhibits all of the Cdks (B). The phosphorylation of pRb by
Cdk4/6 (Cdk2) reverses the growth-suppressive effects of pRb (C). A temporal arrest in the G1 phase or withdrawal from the cell cycle is
thought to be a prerequisite for cell differentiation.
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examination of the mutant mice showed no obvious malfor-
mations. However, they were slightly smaller than wild-type
littermates after weaning [10]. It is possible that this smaller
size of Cdk2-deficient mice might have something to do with
the in vitro finding that the growth-inhibitory effect of
fibroblast growth factor (FGF) on chondrocytes appeared
to be mediated at least partially through the inactivation
of Cyclin E-Cdk2 [11].
2.2. Cdk4
Mice lacking Cdk4 expression (Cdk4neo/neo mice) were
reported to be significantly smaller than their wild-type or
heterozygous littermates. Their smaller size was noticeable
at birth, and the size difference became more apparent
throughout postnatal development. The body weights of
the adult Cdk4-deficient mice were only 50% of that of their
wild-type and heterozygous littermates. An overall reduction
in the size of all of the major organs of the Cdk4-deficient
mice was also observed [12].In contrast, mice expressing a mutant Cdk4 protein that
cannot be down-regulated by the cell cycle inhibitor p16INK4a
(Cdk4R24C/R24C mice) had body weights 5—10% higher than
their wild-type and heterozygous littermates, suggesting the
occurrence of limited, unscheduled cellular proliferation in
at least some tissues [12]. Judging from the phenotypes of
Cdk4neo/neo mice and Cdk4R24C/R24C mice, Cdk4 is thought to
be a positive regulator of skeletogenesis. However, since
Cdk4 bound to Cyclin D1 was shown to be a negative regulator
of Runx2, which is essential for osteoblast differentiation
[13], the mechanisms controlling osteoblast differentiation
and skeletogenesis might be complex. Further studies are
necessary to clarify this issue.
2.3. Cdk6
Mice lacking Cdk6 did not display gross anatomical abnorm-
alities or increased mortality for up to two years of their
lifespan. However, Cdk6-deficient females were slightly
smaller than their wild-type littermates, and they were
reported to attain 85% of the body weight of their wild-type
82 T. Ogasawaralittermates at 12 weeks of age [14]. Although the reason why
Cdk6-null females were small remains to be determined,
their hormonal deficiency was discussed as one of the issues
to be studied [14]. Cdk4 and Cdk6 had been considered to
function redundantly in the G1 phase of the cell cycle, but it is
probable that each protein has one or more distinct role(s) in
skeletogenesis that cannot be compensated for by the other,
considering the difference between Cdk6-deficient mice and
Cdk4-deficient mice. This notion is supported by the fact that
several in vitro studies demonstrated that Cdk6 but not Cdk4
was shown to be down-regulated in the differentiation pro-
cess of osteoblasts, osteoclasts and chondrocytes [15—17].
Moreover, the results of a human genome-wide association
analysis suggested that CDK6 may be associated with adult
height in humans [18].
3. Cyclins
3.1. Cyclin A (A1 and A2)
In mice, Cyclin A1 is expressed exclusively in the germ-cell
lineage and was shown to be essential for spermatocyte
passage into the first meiotic division in male mice [19].
There was no comment on the size, body weight or skeletal
phenotypes of Cyclin-A1 deficient mice [19]. Cyclin A2 proved
to be an essential gene because the homozygous Cyclin A2
null mutant is embryonically lethal [20].
3.2. Cyclin B (B1 and B2)
Cyclin B1 deletion resulted in embryonic lethality, and Cyclin
B1 thus proved to be an essential gene in mice [21]. In
contrast to Cyclin B1, homozygous Cyclin B2-deficient mice
developed normally, and a thorough anatomical and histolo-
gical examination of the mutant mice did not reveal any
obvious malformations. However, in many cases, Cyclin B2-
deficient mice weighed less than their heterozygous litter-
mates. It was suggested that these smaller sizes might be due
to either lower fertility of the males or females or to
embryonic morbidity [21]. In addition, in vitro studies
showed that the hyper-phosphorylation of Runx2 during
mitosis was associated with Cyclin B in osteoblastic cells
[22], and increased cytoplasmic levels of Cyclin B were
observed during the differentiation of osteoblasts [23].
The smaller sizes of Cyclin B2-deficient mice could be attrib-
uted to a defect in such mechanisms. Although Cyclins B1 and
B2 are not G1 cell cycle factors, the mouse models have been
reviewed here because Cyclin B2-deficient mice are unu-
sually small.
3.3. Cyclin D (D1, D2 and D3)
It was reported that all Cyclin D1-deficient mice were abnor-
mally small compared to their heterozygous and wild-type
littermates [24]. During subsequent growth to adulthood,
Cyclin D1-deficient mice remained proportionately smaller
(between 10% and 40%) than their heterozygous littermates,
and they exhibited skeletal abnormalities. Approximately
50% of the Cyclin D1-deficient mice showed a malformation
of the jaw (lateral distortion of the mandibles), and this led
to unchecked growth of the incisor teeth because of theirmisalignment. This malformation of the jaw was not seen in
any wild-type or heterozygous littermates [24].
In contrast to Cyclin D1-deficient mice, Cyclin D2- or
Cyclin D3-deficient mice exhibited no whole-body pheno-
type. Cyclin D2/ mice were reported to be indistinguish-
able phenotypically from their wild-type littermates [25].
Similarly, Cyclin D3-deficient mice were reported to appear
normal during the 1.5 year observation period [26]. Taken
together, the findings indicate that among the D-type cyclins,
Cyclin D1 is apparently a major regulator of skeletogenesis,
and its role in skeletogenesis cannot be compensated for by
Cyclin D2 or Cyclin D3.
3.4. Cyclin E (E1 and E2)
Cyclin E1/mice were reported to be indistinguishable from
their wild-type littermates [27]. In-depth histopathological
analyses showed normal morphogenesis in all tissues exam-
ined. Likewise, mice lacking Cyclin E2 were initially indis-
tinguishable from control littermates. As for Cyclin E1/;
E2/ mice (double-mutant mice), no double-mutant mice
were born alive. Approximately 50% of the double-mutant
mice were alive at embryonic day 10.75, and these mutant
embryos appeared growth-retarded. Geng et al. found that
the tetraploid complementation rescue method fully rescued
the embryonal lethality, and they were able to recover viable
Cyclin E1/; E2/ embryos at all points of development and
at postnatal day 1 [27]. Although Geng et al. reported that
the rescued E1/E2/ mice at postnatal day 1 exhibited a
normal appearance, the mice appeared to have shorter limbs
than their wild-type littermates, judging from the whole-
body photographs presented in their paper.
4. Cip/Kip family
4.1. p21 (Cip1/Waf1)
It was reported that p21/ mice developed normally and
their size was normal; histological sections from several
organs including vertebral bones, muscle, testis, and brain
were examined and were found to be normal [28]. However,
several studies have shown the importance of p21 in osteo-
blast, osteoclast and chondrocyte differentiation [11,29—
32]. It is thus possible that the role of p21 in skeletogenesis
can be compensated for by other CKIs, such as p27 or p57,
which are classified in the Cip/Kip family.
4.2. p27 (Kip1)
The generation and characterization of p27-deficient mice
(p27/ mice) was first reported by three independent
groups at the same time. Nakayama et al. [33] reported that
p27/ mice were not distinguishable at birth from their
wild-type and heterozygous littermates. However, by 4—6
weeks of age, it became evident that many (but not all) p27/
 mice weighed more than the littermate control mice. This
weight difference became more obvious with age. Although
the body size of the p27/mice was increased, the outward
appearances of these mice were normal [33]. Fero et al. [34]
observed that p27/ mice were significantly heavier than
their control littermates, and that p27 heterozygotes were
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at birth, but it became considerable between 2 and 3 weeks
of age and was maximal by 10 weeks of age, and it was
maintained throughout adulthood. Except for their increased
size, p27-deficient mice were morphologically normal. Those
authors considered that an enlargement of all internal organs
was one of the reasons for the increased weight of the p27/
mice [34]. Kiyokawa et al. [35] also reported that the p27/
mice weighed 20—40% more than their littermate controls
after weaning. To determine whether there was a correlation
between weight and growth, they examined skeletal growth
and organ weight. By radiographical analysis, they observed
differences in the length of the skull and longitudinal bones,
including the femur, tibia, and humerus, that corresponded
to the increase in the size of the mice [35]. In accordance
with the phenotypes of p27/mice, there have been reports
indicating that osteogenic differentiation in vitro is asso-
ciated with p27 [36,37].
4.3. p57 (Kip2)
To date, at least three individual groups have generated p57-
deficient mice (p57/ mice), and all groups pointed out
defects in the skeletogenesis of these mice [38—40]. Yan
et al. [38] reported that most p57/ mice died after birth
and displayed various anatomical defects. They also observed
that the heterozygous mice that inherited a maternal tar-
geted allele exhibited similar deficiencies and neonatal
death. The presence of developmental defects in the hetero-
zygous animals was thought to be a consequence of paternal
imprinting in this locus. Developmental defects of p57
mutant mice included cleft palate. The cleft palate seen
in p57/ and imprinted p57+/mice had defects in both the
hard and soft palates. Most p57 mutant mice had short limbs,
a defect attributable to abnormal endochondral ossification
caused by delayed cell cycle exit during chondrocyte differ-
entiation. Since most of the cranial bones (which develop
through intramembranous ossification) in the p57 mutant
mice appeared to be normal, Yan et al. considered that this
defect was specific to bones formed through endochondral
ossification. In agreement with this concept, the interpar-
ietal bone that forms at the base of the skull through
endochondral ossification was also significantly underdeve-
loped in the p57/ mice [38].
Around the same time, Zhang and co-workers also
reported that mice lacking p57 had altered cell proliferation
and differentiation, leading to cleft palate and endochondral
bone ossification defects with incomplete differentiation of
hypertrophic chondrocytes [39]. Takahashi and co-workers
reported the same phenotypes of p57-deficient mice (cleft
palate and defective bone formation, etc.) [40]. Though most
of the p57-deficient mice died within 24 h after birth, about
10% of them survived beyond the weaning period. Those
authors investigated the phenotypes of the surviving p57-
deficient mice and discovered that they all showed severe
growth retardation [40].
Concerning molecular mechanisms, Hirata and co-workers
demonstrated that C/EBPb directly transactivates p57 to
promote the transition of chondrocytes from proliferation
to hypertrophic differentiation during endochondral ossifica-
tion [41], and other studies have also explored the molecularmechanisms of p57 in skeletogenesis [42,43]. In addition to
these in vivo studies, there is evidence of p57 being involved
in the proliferation and differentiation of osteoblasts or
chondrocytes [44—46].
5. INK4 family
5.1. p16 (INK4a)
Serrano et al. reported the phenotype of mice carrying a
targeted deletion of the INK4a locus which eliminated both
p16INK4a and p19ARF [47]. The mice were viable and did not
display gross congenital defects, but they developed spon-
taneous tumors at an early age and were highly responsive to
oncogenic treatments. Sharpless et al. later generated and
characterized p16 Ink4a-specific knockout mice that main-
tained normal p19ARF function; these mice exhibited normal
development except for thymic hyperplasia [48]. It is thus
possible that the role of p16INK4a in skeletogenesis or body
size can be compensated for by other CKIs.
5.2. p15 (INK4b)
Mice deficient in p15INK4b (p15INK4b/mice) were born at the
expected Mendelian ratios, were fertile and did not exhibit
gross morphological or behavioral abnormalities [49]. As in
the case of p16INK4a, it is possible that the role of p15INK4b in
skeletogenesis or body size can be compensated for by other
CKIs.
5.3. p18 (INK4c)
For p18INK4c, wild-type, heterozygous, and null mice
appeared indistinguishable at birth. However, within 2—3
weeks, the p18INK4c/ mice became distinctly larger than
their wild-type littermates. By the end of 1 month, the
p18INK4c/mice were 35—45% larger than their p18INK4c+/+
littermates. The body weights of the p18INK4c/ mice were
increased by 20%, 40%, and 30% at 1, 2, and 3 months,
respectively. There was no obvious difference in the levels
of p18INK4c protein between p18INK4c+/+ and p18INK4c+/ tis-
sues, and there was no significant difference in the body and
organ size between the wild-type and heterozygous mice.
These results suggested that there is no gene dose-depen-
dence for the p18INK4c protein expression [50].
Latres and co-workers [49] also reported that p18INK4c/
mice were larger than their wild-type littermates. However,
the mice generated in their laboratory showed only 20%
weight increases at most compared to the wild-type mice.
They attributed the quantitative differences seen in the two
groups to the different genetic backgrounds of the mice [49].
It is true that p18INK4c was shown to be larger, but the
mechanisms involved are not yet fully understood, and
extensive studies are needed to elucidate the roles of
p18INK4c in skeletogenesis and body size.
5.4. p19 (INK4d)
In a study by Zindy et al. [51], p19INK4d-deficient mice were
born at a normal Mendelian ratio, developed into adulthood,
84 T. Ogasawarahad a normal life span. Except for abnormalities in testicular
size and male germ-cell maturation, no other obvious devel-
opmental anomalies were observed in the p19INK4d-deficient
animals. They did not spontaneously develop tumors [51].
Here again, as in the case of p16INK4a and p15INK4b, it is
possible that the role of p19INK4d in skeletogenesis or body
size can be compensated for by other CKIs. In conclusion,
regarding the INK4 family, these findings raise the hypothesis
that p18INK4c has the most important role in skeletogenesis
and/or body size.
6. Rb gene family
6.1. Rb
Because Rb/ embryos which were generated by a conven-
tional knockout strategy died by the 16th embryonic day, Rb
was shown to be essential for normal mouse development
[52]. In contrast, the Rb+/ mice were developmentally
normal except for a pituitary tumor predisposition with
nearly complete penetrance [52]. In an in vitro study, it
was demonstrated that Rb acts as a transcriptional coacti-
vator of Runx2, which is a master regulator of osteogenic
differentiation [53]. Further studies may elucidate the role of
Rb in skeletogenesis. Toward this end, conditional knockout
strategies using osteoblast- or chondrocyte-specific promo-
ters will be valuable.
6.2. p107
pl07/ and pl07+/ mice did not display any increased
morbidity or mortality up to 24 months of age, and compara-
tive gross and histological surveys of the internal organs of 4—
12-month-old pl07/mice did not reveal any developmental
or pathological abnormalities [54]. However, upon careful
examination of pl07/ embryos, Cobrinik and co-workers
discovered a subtle thickening of the radius, ulna, and
humerus [55].
6.3. p130
It was reported that the size and appearance of homozygous
p130 mutant mice were normal at birth and that these mice
displayed no detected histological abnormalities at birth and
at 2 months of age, and they reproduced normally [55].
Unlike the p107/ embryos, the forelimb development of
pl30/ embryos appeared normal [55].
6.4. Double mutant of Rb and p107
Though Rb+/; pl07/ mice were not distinguishable from
their littermates at birth, they exhibited severe growth
retardation for several weeks, averaging 50% of the weight
of their littermates [54]. The average body weight of 1-week-
old Rb +/; pl07/mice was about one-half of that of Rb+/;
pl07+/ mice, which was equivalent to the other mutant
genotypes and wild-type. This tendency persisted at 2 weeks
of age. Approximately 25% of the Rb+/; pl07/ mice sur-
vived further than 3 weeks of age. Most of these surviving
animals gained weight slowly to reach 70—90% of normalweight after 3 months. Surviving mice subsequently died
from pituitary tumors associated with their Rb+/ status after
12 months. Therefore, it was considered that there was no
apparent additional tumor phenotype associated with this
mutant combination, at least up to 1 year of age [54].
6.5. Double mutant of p107 and p130
In work by Cobrinik et al. [55], pl07+/; pl30+/ compound
heterozygotes appeared normal. However, double homozy-
gous pl07/; pl30/ mice died soon after birth. Although
the neonates were born alive, they had evident breathing
abnormalities and poor oxygenation that were apparent until
they died at various times up to 6 h after birth. On embryonic
day 18.5, the pl07/; pl30/ embryos were up to 30%
smaller than their littermates and they had distinctive exter-
nal features, including dramatically shortened limbs, mod-
erately protruding abdomen, a shortened snout. In addition,
there were obvious aberrations in bone structure and in the
timing of bone deposition in the pl07/; pl30/ embryos.
At 16 days post-coitum (d.p.c.), the pl07/; pl30/
embryos exhibited reduced rib cage size and significantly
reduced bone deposition in each of the long bones of the
limbs. In contrast to the abnormal development of the ribs
and long bones, which form through the process of endo-
chondral ossification, most of the cranial bones (which form
through intramembranous ossification) of the pl07/; pl30/
 embryos developed normally in general.
Concerning the cranium, only the interparietal bone,
which forms at the posterior of the skull through endochon-
dral ossification, was markedly underdeveloped in 19 d.p.c.
pl07/; pl30/ embryos [55]. There was a more subtle
delay detected in the formation of the supraoccipital bone,
which also forms by endochondral ossification. Taken
together, the findings indicate that p107 and p130 are needed
for endochondral but not intramembranous bone develop-
ment.
Regarding the pl07/; pl30+/ mice, although the mice
were within the normal weight range at birth, they attained
only 65% of the normal weight between 2 and 3 weeks of age,
and they died at increased frequency during the first and
second weeks. As described in Section 6.2, since pl07/;
pl30+/+ mice displayed none of these phenotypes, p130 is
thought to have limited ability to compensate for p107 loss in
pl07/; pl30+/ mice. In contrast, p107 was able to com-
pensate more fully for the loss of p130, because the pl07+/;
pl30/ mice showed only a modest and temporary growth
delay from which they recovered at 3 weeks of age. The
finding that developmentally significant growth control by
p107/pl30 is principally restricted to chondrocytes suggests
that these cells may be governed by growth-regulatory pro-
grams [55].
7. Discussion and perspective
The possible involvement of cell cycle factors in skeletogen-
esis and the phenotypes of genetically engineered mouse
models of the G1 cell cycle factors were reviewed, with a
particular focus on the size, weight and skeletal abnormal-
ities of the mice (for this reason, it should be noted that
several important phenotypes of each mouse model, such as
Table 1 Sizes of the genetically engineered mouse models.
Genotype Size
Cdk2/ Slightly small
Cdk4/ Significantly small
Cdk4 R24C/R24C Large
Cdk6/ Slightly small (female)
Cyclin A1/ Not described
Cyclin A2/
(embryonically lethal)
Not applicable
Cyclin B1/
(embryonically lethal)
Not applicable
Cyclin B2/ Small
Cyclin D1/ Significantly small
Cyclin D2/ Normal
Cyclin D3/ Normal
Cyclin E1/ Normal
Cyclin E2/ Normal
Cyclin E/; E2/
(embryonically lethal)
Small?
p21 (Cip1/Waf1)/ Normal
p27 (Kip1)/ Significantly large
p57 (Kip2)/ Small
p16 (INK4a)/ Normal
p15 (INK4b)/ Normal
p18 (INK4c)/ Large
p19 (INK4d)/ Normal
Rb/
(embryonically lethal)
Not applicable
Rb+/ Normal
p107/ Normal
p130/ Normal
Rb+/; pl07/ Small
pl07+/; pl30+/ Normal
pl07/; pl30/ (embryo) Small
pl07/; pl30+/ Small
pl07+/; pl30/ Normal (with modest
and temporary delay)
Table 2 Skeletal abnormalities of genetically engineered
mouse models.
Genotype Skeletal abnormality
Cdk2/ None
Cdk4/ None
Cdk4 R24C/R24C None
Cdk6/ None
Cyclin A1/ Not described
Cyclin A2/
(embryonically lethal)
Not applicable
Cyclin B1/
(embryonically lethal)
Not applicable
Cyclin B2/ None
Cyclin D1/ Malformation of the jaw
Cyclin D2/ None
Cyclin D3/ None
Cyclin E1/ None
Cyclin E2/ None
Cyclin E/; E2/
(embryonically lethal)
Short limbs?
p21 (Cip1/Waf1)/ None
p27 (Kip1)/ None
p57 (Kip2)/ Short limbs and cleft palate
p16 (INK4a)/ None
p15 (INK4b)/ None
p18 (INK4c)/ None
p19 (INK4d)/ None
Rb/
(embryonically lethal)
Not applicable
Rb+/ None
p107/ Subtle thickening of the radius,
ulna, and humerus in embryos
p130/ None
Rb+/; pl07/ Subtle thickening of the radius,
ulna, and humerus in embryos?
pl07+/; pl30+/ None
pl07/; pl30/ Abnormal development of the
ribs and long bones in embryos
pl07/; pl30+/ Abnormal development of the
ribs and long bones in embryos
pl07+/; pl30/ None
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were not discussed herein). As described above and summar-
ized in Tables 1 and 2, several mouse models display pheno-
types in their size and weight. However, body size or weight
does not always reflect bone quantity or quality. Since sig-
nificant skeletal abnormalities are observed in Cyclin D1/,
p57/, Rb +/; pl07/, pl07/; pl30+/ and pl07/;
pl30/ animals, and it can be safely concluded that some
of the G1 cell cycle factors regulate skeletogenesis in vivo,
mainly via endochondral ossification.
It is noteworthy that most of the skeletal abnormalities of
mice seem to be closely associated with the proliferation of
chondrocytes, as seen in the Cyclin D1/, p57/, Rb +/;
pl07/, pl07/; pl30+/ and pl07/; pl30/ animals.
These findings suggested that these cell cycle factors func-
tion as critical regulators of the growth plate chondrocytes,
probably by controlling the transition from proliferation to
hypertrophic differentiation, leading to normal skeletaldevelopment. To this point, although several studies have
investigated the underlying molecular mechanisms [41—43],
the details are still largely unknown and further studies are
desired.
Regarding the in vitro studies, many G1 cell cycle factors
have been reported to control the differentiation of osteo-
blasts, osteoclasts, chondrocytes and other types of cells. For
example, many cell-based studies have demonstrated a cer-
tain correlation between the induction of p21 and/or p27 and
differentiation [29—32,37,56]. Likewise, the potential roles
of Cdks and cyclins in the differentiation of osteoblasts,
osteoclasts or chondrocytes have been studied [15—
17,57,58]. Among these reports, I would like to point out
that we discovered that Cdk6 is a critical regulator of the
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[15—17]. However, it is true that there have been reports
indicating that the role of Cdk6 in osteoclast differentiation
is multifaceted and diverse [57,58], and thus extensive
studies are necessary to accurately clarify the role of Cdk6
in osteoclast differentiation. Nevertheless, because indivi-
dual groups also reported the significance of Cdk6 in the
differentiation of multiple types of cells [59—62], it is appar-
ent that Cdk6 is one of the key regulators in the differentia-
tion of multiple types of cells. This importance of Cdk6 in
differentiation has been emphasized in several review arti-
cles [63—65].
Lastly, I would like to discuss the possibility of cell cycle
factors as targets in bone or cartilage regenerative medicine.
As noted above, several cell cycle factors have been reported
to control differentiation both in vivo and in vitro. In addi-
tion, since cell cycle factors are thought to function down-
stream of various transcription factors, growth factors or
cytokines, etc., if they were used in clinical applications,
their effects might be specific and safe. It is thus natural to
ask whether cell cycle factors might have potential as targets
of regenerative medicine. To address this question, we are
studying the effects of gain- and loss-of-function experi-
ments with several G1 cell cycle factors by overexpression
of their dominant negative form and using gene silencing
through RNA interference or supplementation of inhibitors,
etc. At the present time, it seems that some of the G1 cell
cycle factors could indeed be a candidate target in bone or
cartilage regenerative medicine (Ogasawara et al., unpubl.
data). Our findings will be reported, and we expect that they
will contribute to the greater understanding of regenerative
medicine.
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